Table 2.
The associations between methylation levels of each target and ischemic stroke.
| Targets | CHR | Methylation target position | Length | Number of sites* | Stage 1 | Stage 2 | Combined | |||
|---|---|---|---|---|---|---|---|---|---|---|
| (Start—End, hg19) | (bp) | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |||
| PRDM6_2 | 5 | 122424419–122424583 | 165 | 12 (12) | 0.83 (0.73, 0.95) | 6.55 × 10−03 | 0.47 (0.41, 0.55) | 1.02 × 10−21 | 0.57 (0.51, 0.64) | 3.50 × 10−20 |
| PRDM6_3 | 5 | 122424917–122425111 | 195 | 19 (18) | 0.85 (0.75, 0.96) | 1.04 × 10−02 | 0.50 (0.44, 0.57) | 2.73 × 10−24 | 0.56 (0.50, 0.62) | 1.57 × 10−27 |
| PRDM6_4 | 5 | 122425618–122425772 | 155 | 11 (11) | 0.61 (0.49, 0.76) | 1.16 × 10−05 | 0.34 (0.26, 0.43) | 1.60 × 10−17 | 0.36 (0.30, 0.43) | 1.58 × 10−25 |
| PRDM6_5 | 5 | 122426218–122426384 | 167 | 19 (19) | 0.81 (0.74, 0.89) | 2.19 × 10−05 | 0.73 (0.67, 0.80) | 1.59 × 10−11 | 0.72 (0.67, 0.77) | 3.54 × 10−20 |
| TTBK1 | 6 | 43211012–43211204 | 193 | 12 (3) | 0.97 (0.90, 1.04) | 3.99 × 10−01 | 1.13 (1.06, 1.21) | 5.56 × 10−04 | 1.07 (1.01, 1.14) | 1.48 × 10−02 |
| HDAC9_1 | 7 | 18125758–18126026 | 269 | 18 (14) | 0.82 (0.73, 0.93) | 2.12 × 10−03 | 0.60 (0.53, 0.66) | 1.69 × 10−20 | 0.62 (0.57, 0.68) | 2.12 × 10−25 |
| IGFBP3_2 | 7 | 45960262–45960480 | 219 | 28 (28) | 0.92 (0.82, 1.04) | 1.79 × 10−01 | 0.64 (0.58, 0.70) | 2.20 × 10−20 | 0.66 (0.61, 0.71) | 1.04 × 10−25 |
| IGFBP3_3 | 7 | 45960753–45960958 | 206 | 22 (22) | 0.92 (0.83, 1.02) | 1.12 × 10−01 | 0.64 (0.57, 0.71) | 2.65 × 10−15 | 0.71 (0.65, 0.77) | 2.71 × 10−14 |
| LRRC10B_1 | 11 | 61275868–61276114 | 247 | 19 (13) | 0.70 (0.55, 0.90) | 5.73 × 10−03 | 0.49 (0.40, 0.60) | 6.81 × 10−12 | 0.49 (0.41, 0.58) | 2.95 × 10−16 |
| LRRC10B_2 | 11 | 61276891–61277075 | 185 | 23 (11) | 0.85 (0.74, 0.97) | 1.85 × 10−02 | 0.69 (0.59, 0.80) | 2.39 × 10−06 | 0.69 (0.61, 0.78) | 1.36 × 10−09 |
| SYT7_1 | 11 | 61348165–61348388 | 224 | 31 (31) | 0.71 (0.88, 0.58) | 1.20 × 10−03 | 0.22 (0.18, 0.28) | 1.13 × 10−38 | 0.29 (0.25, 0.34) | 2.32 × 10−44 |
| PDE3A_1 | 12 | 20521690–20521926 | 237 | 22 (21) | 0.94 (0.88, 1.00) | 4.75 × 10−02 | 0.55 (0.50, 0.60) | 2.57 × 10−33 | 0.68 (0.64, 0.73) | 7.60 × 10−28 |
| PDE3A_2 | 12 | 20522200–20522368 | 169 | 16 (16) | 0.86 (0.80, 0.93) | 1.26 × 10−04 | 0.58 (0.53, 0.63) | 5.24 × 10−37 | 0.65 (0.61, 0.69) | 1.16 × 10−36 |
| PDE3A_3 | 12 | 20522826–20523046 | 221 | 14 (14) | 0.86 (0.78, 0.95) | 3.60 × 10−03 | 0.49 (0.44, 0.55) | 1.82 × 10−36 | 0.56 (0.52, 0.61) | 1.13 × 10−38 |
| TBX2_1 | 17 | 59475132–59475331 | 200 | 13 (11) | 0.99 (0.97, 1.01) | 2.26 × 10−01 | 0.97 (0.94, 1.00) | 2.06 × 10−02 | 0.98 (0.96, 1.00) | 2.28 × 10−02 |
| TBX2_2 | 17 | 59475409–59475636 | 228 | 11 (5) | 0.91 (0.87, 0.95) | 5.73 × 10−05 | 0.89 (0.84, 0.94) | 1.40 × 10−04 | 0.90 (0.86, 0.94) | 8.54 × 10−06 |
| TBX2_3 | 17 | 59476394–59476620 | 227 | 22 (19) | 0.84 (0.73, 0.96) | 9.46 × 10−03 | 0.52 (0.45, 0.60) | 1.03 × 10−19 | 0.57 (0.51, 0.64) | 4.08 × 10−22 |
| C17orf82_2 | 17 | 59488091–59488288 | 198 | 15 (12) | 0.81 (0.67, 0.99) | 4.10 × 10−02 | 0.95 (0.78, 1.15) | 5.87 × 10−01 | 0.89 (0.76, 1.05) | 1.68 × 10−01 |
| C17orf82_3 | 17 | 59488839–59489012 | 174 | 15 (13) | 0.81 (0.72, 0.91) | 3.74 × 10−04 | 0.67 (0.59, 0.75) | 3.70 × 10−11 | 0.67 (0.61, 0.74) | 1.79 × 10−16 |
| C17orf82_5 | 17 | 59490117–59490276 | 160 | 14 (14) | 0.76 (0.61, 0.94) | 1.20 × 10−02 | 0.46 (0.36, 0.60) | 3.88 × 10−09 | 0.53 (0.44, 0.65) | 2.82 × 10−10 |
| AMH_3 | 19 | 2252326–2252568 | 243 | 21 (21) | 0.93 (0.86, 1.00) | 6.75 × 10−02 | 0.52 (0.47, 0.57) | 4.05 × 10−38 | 0.63 (0.59, 0.68) | 1.59 × 10−33 |
CHR, Chromosome; CI, Confidence interval; OR, Odds ratio. ORs and 95% CIs per 5% increase in methylation levels were calculated. The associations were adjusted for age, sex, smoking, drinking, BMI, hypertension, type 2 diabetes, TC, TG, HDL-C and LDL-C.
*
Number of methylation sites tested in each target. Numbers in the bracket indicate the number of methylation sites that were significantly associated with ischemic stroke in each of the targets. The methylation level of a target was the mean methylation level of the sites in the target.